Amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig’s disease, is a progressive neurodegenerative disorder that attacks the motor neurons controlling voluntary muscle movement. Roughly 30,000 Americans are estimated to be living with the disease at any given time, and several thousand new cases are diagnosed each year, according to the CDC National ALS Registry and the NINDS. It is a hard diagnosis, and this guide approaches it with that in mind. Despite its reputation, the field has changed meaningfully in the past decade — disease-modifying therapies now exist, multidisciplinary care improves both survival and quality of life, and a large roster of clinical trials offers options that previous generations of patients did not have.
How ALS Damages the Body
ALS affects both the upper motor neurons in the brain and the lower motor neurons in the spinal cord. As these cells decline, the muscles they control progressively weaken, twitch, and atrophy. Importantly, ALS does not typically damage sensation, bowel and bladder function, or the muscles of the eyes — meaning many patients remain fully aware and able to think and feel as their bodies change, which is part of what makes the disease so difficult.
Roughly 90 to 95 percent of cases are sporadic, with no clear family history. The remaining 5 to 10 percent are familial, often linked to mutations in genes such as C9orf72, SOD1, FUS, or TARDBP. Per MedlinePlus Genetics, C9orf72 accounts for a large share of familial cases in the US and Europe, while SOD1 causes roughly 15 to 20 percent of familial ALS. Average age at onset is generally in the late 50s to 60s, though younger-onset cases occur.
Early Symptoms Are Often Subtle
Initial complaints depend on where motor neuron loss begins. About two-thirds of patients present with limb-onset symptoms — a foot that drops, a hand that drops things, calf cramps that do not resolve, or one arm that tires faster than the other. Bulbar-onset ALS, which begins in the muscles of the face and throat, accounts for the remaining third and shows up as slurred speech, choking on liquids, or unprovoked tongue twitching.
Fasciculations — visible muscle twitches under the skin — are a hallmark, but on their own they do not indicate ALS. Most people with twitching muscles have benign fasciculation syndrome and never develop ALS. The combination of weakness, atrophy, hyperreflexia, and progressive spread is what raises concern and prompts a neurologist to investigate further.
Diagnosis Takes Time
The average time from first symptom to confirmed diagnosis is often around 10 to 16 months, partly because no single test confirms ALS. The workup includes electromyography (EMG) showing widespread motor neuron changes, nerve conduction studies, MRI to rule out spinal cord compression or stroke, and bloodwork to exclude mimics such as myasthenia gravis, multifocal motor neuropathy, and lead toxicity.
Newer diagnostic frameworks — the Gold Coast criteria published in 2020 — simplified the older El Escorial system and have helped shorten diagnostic delay in many centers. Mayo Clinic notes that experienced ALS centers reduce diagnostic delay and connect patients to multidisciplinary care faster, which is one reason an early referral matters.
Disease Progression
Median survival from symptom onset is commonly cited as 2 to 5 years, though roughly 10 percent of patients live 10 years or more, and MedlinePlus describes death from respiratory failure typically within 2 to 10 years of symptom onset. Stephen Hawking, who lived more than 50 years with the disease, was a famous outlier. Faster progression tends to correlate with bulbar onset, older age, and rapid early decline; slower progression correlates with limb onset, younger age, and certain genetic variants. Every person’s course is different, and averages cannot predict any one individual’s path.
The functional rating scale (ALSFRS-R) tracks decline across 12 domains scored 0 to 4. A typical patient loses about one point per month, though this varies widely. As respiratory muscles weaken, vital capacity falls and patients eventually require breathing support.
When to seek emergency care: Call 911 or go to the nearest emergency room if a person with ALS develops sudden severe shortness of breath, choking that does not resolve, blue lips or fingernails, confusion or unusual sleepiness (possible signs of CO2 retention), or chest pain. Respiratory compromise is the leading cause of death in ALS and can develop more rapidly than expected during infections.
Current Treatments
There is no cure for ALS, but there are FDA-approved disease-modifying options, and all of them are prescriber-directed. Riluzole, approved in 1995, extends survival by an average of a few months. Edaravone (Radicava), available as an IV infusion or oral suspension, modestly slows functional decline in selected patients. Tofersen (Qalsody), approved in 2023, targets SOD1-mediated ALS — a small percentage of cases — and has shown biomarker effects; it is used only in people with a confirmed SOD1 mutation.
An important update: Relyvrio (AMX0035, sodium phenylbutyrate and taurursodiol) was approved in 2022 but was withdrawn from the US and Canadian markets in 2024 after its Phase 3 PHOENIX trial did not show a significant benefit over placebo (Amylyx announced the market withdrawal around April 2024). If you read older articles that list it as an available ALS drug, that information is out of date — verify the current, approved drug list with your neurologist or ALS clinic, as the landscape continues to change.
Beyond pharmacotherapy, multidisciplinary ALS clinics are associated with improved survival — estimated in cohort studies at roughly 6 to 12 additional months — as summarized in reviews on PMC. These clinics combine neurology, pulmonology, nutrition, speech therapy, physical therapy, social work, and palliative care under one roof, usually monthly, so care is coordinated rather than fragmented.
Symptom management makes a major quality-of-life difference. Spasticity may respond to baclofen and tizanidine. Cramps may improve with clinician-selected medication. Pseudobulbar affect — uncontrolled laughing or crying — can be treated with dextromethorphan-quinidine. Sialorrhea (excess saliva) responds to anticholinergic treatments or salivary gland botulinum toxin injections. These are all prescribed and adjusted by the care team, not self-managed.
Respiratory and Nutritional Support
Non-invasive ventilation (BiPAP) extends life and dramatically improves comfort, often started as forced vital capacity drops toward 50 percent of predicted, and sometimes earlier based on symptoms. Many patients use it overnight first, then expand to daytime as needed. Tracheostomy with invasive ventilation can extend life further but is chosen by a minority of US patients after careful goals-of-care discussion.
Feeding tube placement (PEG) is generally recommended before significant respiratory decline because the procedure is safer at higher vital capacities. Nutrition affects survival; unintended weight loss is an independent predictor of faster decline, so nutrition is monitored closely.
Living With ALS
Cognitive changes affect a meaningful share of patients — roughly half have some degree of change, and about 15 percent meet criteria for frontotemporal dementia. This overlap reflects shared genetics, particularly the C9orf72 expansion that can cause both conditions. Families and the care team stay alert to executive-function and behavioral changes that can complicate decision-making, approaching them with patience rather than judgment.
Adaptive equipment evolves as the disease progresses, from simple ankle-foot orthoses to power wheelchairs with eye-gaze-controlled communication devices that let people keep expressing themselves. The ALS Association loan closets distribute donated equipment at no charge in many regions, and local chapters help families navigate resources. Our broader guide to chronic conditions touches on caregiving costs that often exceed insurance coverage.
Emotional support matters as much as physical care. An ALS diagnosis carries a heavy psychological burden for patients and caregivers alike, and feelings of grief, fear, and depression are understandable and common. Support is available, and reaching out is a sign of strength. Mental health care, ALS Association support groups, and palliative-care teams can all help. If you or someone you love is struggling emotionally or having thoughts of self-harm, call or text the 988 Suicide & Crisis Lifeline (dial or text 988 in the US), which is free and available 24/7. In an immediate emergency, call 911.
Clinical Trials and What’s Coming
The therapeutic pipeline is among the largest in ALS history. Antisense oligonucleotides targeting genes such as C9orf72 and FUS, cell-based therapies, and small molecules aimed at neuroinflammation are all in active trials. The HEALEY ALS Platform Trial at Massachusetts General Hospital tests multiple drugs simultaneously against a shared placebo group, accelerating evaluation. Trial results vary, and not every promising candidate succeeds — the Relyvrio experience is a reminder to weigh early enthusiasm against confirmed evidence.
Patients can find trials through ClinicalTrials.gov and the ALS Association’s research resources. Genetic testing is increasingly recommended at diagnosis because some trials enroll only specific mutation carriers, and because a SOD1 result can open the door to tofersen. Decisions about testing and trials are best made with a neurologist and, where relevant, a genetic counselor.
When to See a Doctor
Progressive painless weakness, especially asymmetric weakness in a single limb, deserves prompt neurology evaluation. So does new dysarthria (slurred speech), dysphagia (difficulty swallowing), or unexplained weight loss. Fasciculations alone do not warrant alarm, but combined with weakness or atrophy they merit a workup.
Many clinicians recommend referral to an ALS Association Certified Treatment Center of Excellence once the diagnosis is suspected — even before it is confirmed — because earlier multidisciplinary involvement consistently correlates with better outcomes and better support for the whole family.
Frequently Asked Questions
Is ALS painful?
ALS itself does not directly cause pain because sensory nerves are usually spared, but secondary pain from muscle cramps, joint stiffness, and pressure points is common — affecting a majority of patients over time. Most such pain responds to clinician-directed medications, physical therapy, and proper positioning.
Can ALS be inherited?
About 5 to 10 percent of cases are familial, with one of the most common causes being a hexanucleotide repeat expansion in C9orf72. Genetic counseling is offered to first-degree relatives of familial cases. The remaining majority are sporadic with no clear inheritance pattern.
What causes ALS?
The cause remains incompletely understood. Current theories implicate protein misfolding, glutamate excitotoxicity, mitochondrial dysfunction, and neuroinflammation. Military service, certain occupational exposures, and other factors have been associated with elevated risk in epidemiological studies, though causation remains debated and no single environmental cause is established.
How is ALS different from MS?
Multiple sclerosis attacks the myelin sheath around nerves and is autoimmune; ALS involves the loss of motor neurons themselves. MS typically presents with relapses and remissions; ALS generally progresses steadily. Sensation is often affected in MS but usually preserved in ALS. Our multiple sclerosis guide details those differences.
Is there any hope after an ALS diagnosis?
Yes — while ALS is not curable, treatments can slow decline for some people, multidisciplinary care extends and improves life, and research is moving quickly. Many patients and families find meaning, connection, and good quality of life with the right support in place. A neurologist and an ALS clinic can help you build that plan.
The Bottom Line
ALS remains incurable, but the trajectory is no longer one of helpless waiting. Multidisciplinary clinics extend survival, approved disease-modifying drugs (riluzole, edaravone, and tofersen for SOD1-ALS) are available, and dozens of investigational therapies are in trials — even as some candidates, like Relyvrio, are withdrawn when the evidence does not hold up. Connecting early with an ALS Association Certified Center, considering genetic testing, and engaging palliative care alongside active treatment all improve quality of life. Patients and families who navigate this disease most successfully tend to make decisions about ventilation, feeding, and goals of care while still able to communicate clearly — long before a crisis forces those choices. Above all, no one should face ALS alone; help, both medical and emotional, is available.
TL;DR: ALS is a progressive motor neuron disease that weakens voluntary muscles while usually sparing sensation, eyes, and continence. It is diagnosed over time with EMG, MRI, and bloodwork to rule out mimics. There is no cure, but riluzole, edaravone, and tofersen (SOD1-only) can help some people, and multidisciplinary clinic care plus timed breathing and nutrition support extend and improve life. Relyvrio was withdrawn in 2024 — confirm current drugs with a neurologist. Support is available; the 988 Suicide & Crisis Lifeline is there 24/7.
This article is for general education only and is not medical advice. It does not replace a neurologist or ALS care team, and treatment must be individualized. Drug approvals change; verify the current options with your clinician. If you are in emotional distress, call or text 988 (US); in an emergency, call 911.
Sources
- NINDS — Amyotrophic Lateral Sclerosis (ALS)
- MedlinePlus Genetics — Amyotrophic lateral sclerosis
- ALS Association — Care, support, and Certified Treatment Centers of Excellence
- Mayo Clinic — ALS diagnosis and treatment
- Amylyx / FDA — Relyvrio (AMX0035) PHOENIX Phase 3 results and 2024 US market withdrawal
- 988 Suicide & Crisis Lifeline — 988lifeline.org